近日,随着碧生源2024财年年报的发布,这家在保健茶领域颇具影响力的企业再度成为行业焦点。2024年1月1日至12月31日期间,碧生源实现营业收入4.84亿元,归属母公司净利润1480.40万元,同比扭亏为盈。在其业务布局中,OTC药品实行单体药店运营的策略调整,尤为引人注目,这一举措旨在更加贴近顾客购买需求。碧生源控股有限公司长期致力于功能保健茶产品的研究、开发、生产、推广及销售。近年来,随着...
Source Link近日,随着碧生源2024财年年报的发布,这家在保健茶领域颇具影响力的企业再度成为行业焦点。2024年1月1日至12月31日期间,碧生源实现营业收入4.84亿元,归属母公司净利润1480.40万元,同比扭亏为盈。在其业务布局中,OTC药品实行单体药店运营的策略调整,尤为引人注目,这一举措旨在更加贴近顾客购买需求。碧生源控股有限公司长期致力于功能保健茶产品的研究、开发、生产、推广及销售。近年来,随着...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.